http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011102262-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2009-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011102262-A |
| titleOfInvention | NUTRIGENOMIC METHODS AND COMPOSITIONS |
| abstract | 1. The use of one or more compositions to produce one or more drugs that are used together to treat a disease or condition selected from the group consisting of satisfaction deficit syndrome (RDS), substance use disorder (SUD), acute or chronic pain, inflammation, joint damage, stress, anxiety, insomnia, insomnia, lethargy, attention deficit hyperactivity disorder, depression and premenstrual dysphoric disorder, where the composite tion (s) is administered to a patient whose genotype is determined and correlated with the disease or condition, wherein the composition (i) comprises at least the following substances: a. an opiate disruption inhibiting amount of at least one of a substance selected from the group consisting of a D-amino acid, a peptide and a structural analogue or derivative of a D-amino acid or peptide; ! b. a neurotransmitter synthesis promoting quantity of at least one neurotransmitter precursor selected from the group consisting of dopamine precursor, optionally L-Tyr, L-Phe or L-Dopa; a serotonin precursor, optionally L-Trp or 5-hydroxytryptophan; and a gamma-aminobutyric acid precursor (GABA), optionally L-glutamine, 1-glutamate or L-glutamic acid; and! with. an increase in tryptophan concentration of at least one chromium salt; and! d. catecholamine catalysis inhibitor caused by the enzyme catecholamine-o-methyltransferase (COMT), optionally selected from the group consisting of any form of rhodiola and chupersin,! where substances (a) - (d) are administered as part of one or more comp |
| priorityDate | 2008-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 738.